MXPA03009711A - Vacuna contra la viruela. - Google Patents
Vacuna contra la viruela.Info
- Publication number
- MXPA03009711A MXPA03009711A MXPA03009711A MXPA03009711A MXPA03009711A MX PA03009711 A MXPA03009711 A MX PA03009711A MX PA03009711 A MXPA03009711 A MX PA03009711A MX PA03009711 A MXPA03009711 A MX PA03009711A MX PA03009711 A MXPA03009711 A MX PA03009711A
- Authority
- MX
- Mexico
- Prior art keywords
- vaccinia virus
- strain
- dryvax
- virus
- same
- Prior art date
Links
- 229940083538 smallpox vaccine Drugs 0.000 title description 3
- 229960005486 vaccine Drugs 0.000 claims abstract description 65
- 241000700618 Vaccinia virus Species 0.000 claims abstract description 61
- 241000700647 Variola virus Species 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 28
- 230000002238 attenuated effect Effects 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 24
- 238000004113 cell culture Methods 0.000 claims description 19
- 238000012360 testing method Methods 0.000 claims description 18
- 230000001018 virulence Effects 0.000 claims description 17
- 230000001681 protective effect Effects 0.000 claims description 10
- 108091008146 restriction endonucleases Proteins 0.000 claims description 10
- 230000029087 digestion Effects 0.000 claims description 8
- 230000012010 growth Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 230000005847 immunogenicity Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 210000004748 cultured cell Anatomy 0.000 claims description 3
- 230000001902 propagating effect Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 241000700605 Viruses Species 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 19
- 206010046865 Vaccinia virus infection Diseases 0.000 description 18
- 208000007089 vaccinia Diseases 0.000 description 18
- 238000002255 vaccination Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 244000309466 calf Species 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 229940125575 vaccine candidate Drugs 0.000 description 5
- 208000001203 Smallpox Diseases 0.000 description 4
- 241000870995 Variola Species 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000008029 eradication Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000007917 intracranial administration Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000700629 Orthopoxvirus Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000003186 pharmaceutical solution Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 241000700626 Cowpox virus Species 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000005871 monkeypox Diseases 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 230000005156 neurotropism Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24161—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/840,751 US6723325B1 (en) | 2001-04-23 | 2001-04-23 | Smallpox vaccine |
| PCT/US2002/012616 WO2002085411A1 (en) | 2001-04-23 | 2002-04-23 | Smallpox vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03009711A true MXPA03009711A (es) | 2005-03-07 |
Family
ID=25283120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03009711A MXPA03009711A (es) | 2001-04-23 | 2002-04-23 | Vacuna contra la viruela. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US6723325B1 (https=) |
| EP (1) | EP1381389B1 (https=) |
| JP (1) | JP4397591B2 (https=) |
| KR (1) | KR20040063083A (https=) |
| CN (1) | CN1527722A (https=) |
| AU (1) | AU2002258910B2 (https=) |
| BR (1) | BR0209145A (https=) |
| CA (1) | CA2444747C (https=) |
| CZ (1) | CZ305819B6 (https=) |
| EA (1) | EA007656B1 (https=) |
| ES (1) | ES2546612T3 (https=) |
| HU (1) | HU228401B1 (https=) |
| IL (2) | IL158549A0 (https=) |
| MA (1) | MA26270A1 (https=) |
| MX (1) | MXPA03009711A (https=) |
| NZ (1) | NZ529265A (https=) |
| PL (1) | PL212117B1 (https=) |
| WO (1) | WO2002085411A1 (https=) |
| ZA (1) | ZA200309084B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645456B2 (en) * | 2001-04-23 | 2010-01-12 | Sanofi Pasteur Biologics Co. | Vaccinia virus strains |
| US6723325B1 (en) * | 2001-04-23 | 2004-04-20 | Acambis, Inc. | Smallpox vaccine |
| US20090269365A1 (en) * | 2005-04-20 | 2009-10-29 | University Of Washington | Immunogenic vaccinia peptides and methods of using same |
| MX2009004862A (es) | 2006-11-07 | 2009-07-17 | Sanofi Pasteur Biologics Co | Estabilizacion de vacunas por liofilizacion. |
| KR100859345B1 (ko) * | 2006-12-12 | 2008-09-19 | 씨제이제일제당 (주) | 세포배양에 의해 두창 백신을 생산하는 방법 및 그에 의해생산된 두창 백신 |
| ES2733211T3 (es) * | 2011-04-15 | 2019-11-28 | Genelux Corp | Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas |
| RU2496149C1 (ru) * | 2012-06-19 | 2013-10-20 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") | Способ оценки противооспенной активности лечебно-профилактических препаратов |
| JP2019535311A (ja) | 2016-11-02 | 2019-12-12 | デイビッド エバンス， | 合成キメラポックスウイルス |
| EP3788142A4 (en) | 2018-05-02 | 2022-04-27 | Tonix Pharma Holdings Limited | SYNTHETIC CHIMERIC VACCINE VIRUS |
| US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
| CA3116192C (en) | 2018-11-06 | 2025-09-23 | Calidi Biotherapeutics (Nevada), Inc. | IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY |
| WO2025184411A1 (en) | 2024-02-27 | 2025-09-04 | Calidi Biotherapeutics (Nevada), Inc. | Serum-resistant eev viruses and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4315914A (en) * | 1980-04-04 | 1982-02-16 | Seiji Arakawa | Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof |
| JPS60202827A (ja) | 1984-03-28 | 1985-10-14 | Chibaken | 弱毒痘そうワクチン株 |
| US5614193A (en) * | 1991-11-14 | 1997-03-25 | The United States Of America As Represented By The Secretary Of The Army | Hantavirus vaccine |
| US5656465A (en) * | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
| US6723325B1 (en) | 2001-04-23 | 2004-04-20 | Acambis, Inc. | Smallpox vaccine |
-
2001
- 2001-04-23 US US09/840,751 patent/US6723325B1/en not_active Expired - Lifetime
-
2002
- 2002-04-23 PL PL373958A patent/PL212117B1/pl unknown
- 2002-04-23 KR KR10-2003-7013866A patent/KR20040063083A/ko not_active Ceased
- 2002-04-23 HU HU0303878A patent/HU228401B1/hu unknown
- 2002-04-23 BR BR0209145-3A patent/BR0209145A/pt active Search and Examination
- 2002-04-23 CN CNA028126335A patent/CN1527722A/zh active Pending
- 2002-04-23 EP EP02728888.5A patent/EP1381389B1/en not_active Expired - Lifetime
- 2002-04-23 AU AU2002258910A patent/AU2002258910B2/en not_active Ceased
- 2002-04-23 EA EA200301151A patent/EA007656B1/ru not_active IP Right Cessation
- 2002-04-23 IL IL15854902A patent/IL158549A0/xx unknown
- 2002-04-23 JP JP2002582984A patent/JP4397591B2/ja not_active Expired - Fee Related
- 2002-04-23 ES ES02728888.5T patent/ES2546612T3/es not_active Expired - Lifetime
- 2002-04-23 WO PCT/US2002/012616 patent/WO2002085411A1/en not_active Ceased
- 2002-04-23 CZ CZ2003-3184A patent/CZ305819B6/cs not_active IP Right Cessation
- 2002-04-23 MX MXPA03009711A patent/MXPA03009711A/es active IP Right Grant
- 2002-04-23 NZ NZ529265A patent/NZ529265A/en not_active IP Right Cessation
- 2002-04-23 CA CA2444747A patent/CA2444747C/en not_active Expired - Lifetime
-
2003
- 2003-05-27 US US10/445,671 patent/US7115270B2/en not_active Expired - Lifetime
- 2003-10-22 IL IL158549A patent/IL158549A/en unknown
- 2003-11-17 MA MA27401A patent/MA26270A1/fr unknown
- 2003-11-21 ZA ZA2003/09084A patent/ZA200309084B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7115270B2 (en) | 2006-10-03 |
| JP4397591B2 (ja) | 2010-01-13 |
| EP1381389A1 (en) | 2004-01-21 |
| HUP0303878A3 (en) | 2010-01-28 |
| ES2546612T3 (es) | 2015-09-25 |
| KR20040063083A (ko) | 2004-07-12 |
| WO2002085411A1 (en) | 2002-10-31 |
| US6723325B1 (en) | 2004-04-20 |
| PL373958A1 (en) | 2005-09-19 |
| AU2002258910B2 (en) | 2007-10-25 |
| EP1381389B1 (en) | 2015-08-26 |
| CA2444747A1 (en) | 2002-10-31 |
| US20060153873A1 (en) | 2006-07-13 |
| CZ20033184A3 (cs) | 2004-04-14 |
| ZA200309084B (en) | 2005-01-26 |
| HU228401B1 (en) | 2013-03-28 |
| CA2444747C (en) | 2018-04-17 |
| PL212117B1 (pl) | 2012-08-31 |
| NZ529265A (en) | 2006-04-28 |
| HK1062804A1 (zh) | 2004-11-26 |
| EA007656B1 (ru) | 2006-12-29 |
| EA200301151A1 (ru) | 2004-10-28 |
| IL158549A (en) | 2009-07-20 |
| MA26270A1 (fr) | 2004-09-01 |
| BR0209145A (pt) | 2005-04-19 |
| IL158549A0 (en) | 2004-05-12 |
| HUP0303878A2 (hu) | 2004-03-01 |
| CN1527722A (zh) | 2004-09-08 |
| EP1381389A4 (en) | 2004-07-28 |
| JP2005503126A (ja) | 2005-02-03 |
| CZ305819B6 (cs) | 2016-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7645456B2 (en) | Vaccinia virus strains | |
| Sikes et al. | Effective protection of monkeys against death from street virus by post-exposure administration of tissue-culture rabies vaccine | |
| Henle | Interference phenomena between animal viruses: a review | |
| AU2003239805B2 (en) | Modified vaccinia virus ankara for the vaccination of neonates | |
| Pratt et al. | Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models | |
| CA2444747C (en) | Smallpox vaccine | |
| Kaplan | Vaccinia virus: a suitable vehicle for recombinant vaccines? | |
| AU2002258910A1 (en) | Smallpox vaccine | |
| HUE025635T2 (en) | Immediate protection against pathogens through MVA | |
| Jarouliya et al. | Developing Vaccine Against COVID-19 and Immune Response | |
| CA2501220C (en) | Vaccines against west nile virus | |
| HK1062804B (en) | Smallpox vaccine | |
| US20070154455A1 (en) | Monoparamunity inducers based on attenuated rabbit myxoma viruses | |
| Saeed et al. | Monkey Pox: An Emerging Outbreak: Monkey Pox: An Emerging Outbreak | |
| RU2781070C1 (ru) | Живая аттенуированная культуральная вакцина для профилактики натуральной оспы и других ортопоксвирусных инфекций на основе вируса осповакцины и способы ее получения и применения | |
| Kara | Questions on Immunization and Vaccination and Short Answers | |
| Coşkun et al. | Questions on Immunization and Vaccination and Short Answers | |
| Melnick | Poliomyelitis vaccination: what are the options? | |
| WO2021242879A1 (en) | Live attenuated strains of foot and mouth disease modified by deoptimization and uses thereof | |
| EP4162030A1 (en) | Live attenuated strains of foot and mouth disease modified by deoptimization and uses thereof | |
| Smedberg | Determining the Innate and Adaptive Immune Responses to Vesicular Stomatitis Virus Vaccine Vectors | |
| Seal | Prevention of Smallpox by Vaccination and Revaccination: A Critical Study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| HC | Change of company name or juridical status |